S&P 500   5,072.96 (-0.10%)
DOW   38,900.85 (-0.18%)
QQQ   436.42 (-0.27%)
AAPL   181.22 (-0.77%)
MSFT   407.46 (+0.00%)
META   486.87 (-0.04%)
GOOGL   136.02 (-2.06%)
AMZN   173.72 (+0.10%)
TSLA   204.31 (+2.29%)
NVDA   787.20 (+0.02%)
NIO   5.52 (-4.50%)
AMD   176.17 (-1.03%)
BABA   75.37 (-2.97%)
T   17.01 (+1.07%)
F   12.29 (+2.42%)
MU   89.75 (-2.29%)
CGC   3.50 (-0.85%)
GE   155.12 (+0.73%)
DIS   110.78 (+1.24%)
AMC   5.03 (+4.57%)
PFE   27.10 (+0.78%)
PYPL   60.85 (+1.15%)
XOM   104.36 (+0.32%)
S&P 500   5,072.96 (-0.10%)
DOW   38,900.85 (-0.18%)
QQQ   436.42 (-0.27%)
AAPL   181.22 (-0.77%)
MSFT   407.46 (+0.00%)
META   486.87 (-0.04%)
GOOGL   136.02 (-2.06%)
AMZN   173.72 (+0.10%)
TSLA   204.31 (+2.29%)
NVDA   787.20 (+0.02%)
NIO   5.52 (-4.50%)
AMD   176.17 (-1.03%)
BABA   75.37 (-2.97%)
T   17.01 (+1.07%)
F   12.29 (+2.42%)
MU   89.75 (-2.29%)
CGC   3.50 (-0.85%)
GE   155.12 (+0.73%)
DIS   110.78 (+1.24%)
AMC   5.03 (+4.57%)
PFE   27.10 (+0.78%)
PYPL   60.85 (+1.15%)
XOM   104.36 (+0.32%)
S&P 500   5,072.96 (-0.10%)
DOW   38,900.85 (-0.18%)
QQQ   436.42 (-0.27%)
AAPL   181.22 (-0.77%)
MSFT   407.46 (+0.00%)
META   486.87 (-0.04%)
GOOGL   136.02 (-2.06%)
AMZN   173.72 (+0.10%)
TSLA   204.31 (+2.29%)
NVDA   787.20 (+0.02%)
NIO   5.52 (-4.50%)
AMD   176.17 (-1.03%)
BABA   75.37 (-2.97%)
T   17.01 (+1.07%)
F   12.29 (+2.42%)
MU   89.75 (-2.29%)
CGC   3.50 (-0.85%)
GE   155.12 (+0.73%)
DIS   110.78 (+1.24%)
AMC   5.03 (+4.57%)
PFE   27.10 (+0.78%)
PYPL   60.85 (+1.15%)
XOM   104.36 (+0.32%)
S&P 500   5,072.96 (-0.10%)
DOW   38,900.85 (-0.18%)
QQQ   436.42 (-0.27%)
AAPL   181.22 (-0.77%)
MSFT   407.46 (+0.00%)
META   486.87 (-0.04%)
GOOGL   136.02 (-2.06%)
AMZN   173.72 (+0.10%)
TSLA   204.31 (+2.29%)
NVDA   787.20 (+0.02%)
NIO   5.52 (-4.50%)
AMD   176.17 (-1.03%)
BABA   75.37 (-2.97%)
T   17.01 (+1.07%)
F   12.29 (+2.42%)
MU   89.75 (-2.29%)
CGC   3.50 (-0.85%)
GE   155.12 (+0.73%)
DIS   110.78 (+1.24%)
AMC   5.03 (+4.57%)
PFE   27.10 (+0.78%)
PYPL   60.85 (+1.15%)
XOM   104.36 (+0.32%)
NASDAQ:CNTG

Centogene (CNTG) Stock Price, News & Analysis

$0.76
-0.02 (-1.95%)
(As of 11:53 AM ET)
Today's Range
$0.75
$0.79
50-Day Range
$0.77
$1.26
52-Week Range
$0.61
$2.52
Volume
11,644 shs
Average Volume
17,490 shs
Market Capitalization
$20.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.50

Centogene MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
89.9% Upside
$1.50 Price Target
Short Interest
Healthy
0.07% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.26
Upright™ Environmental Score
News Sentiment
0.62mentions of Centogene in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.60) to ($0.97) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.29 out of 5 stars

Medical Sector

195th out of 944 stocks

Medical Laboratories Industry

8th out of 22 stocks


CNTG stock logo

About Centogene Stock (NASDAQ:CNTG)

Centogene N.V., together with its subsidiaries, engages in the research and development of products for human genetics in Europe, the Middle East, North America, Latin America, and the Asia Pacific. It provides data-driven answers to patients, physicians, and pharmaceutical companies for rare and neurodegenerative diseases. It operates through two segments: Pharmaceutical and Diagnostics. The company provides target and drug screening, clinical development, market access and expansion, as well as CENTOGENE Biodatabank licenses and insight report services. In addition, it offers various services, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. Centogene N.V. was founded in 2006 and is headquartered in Rostock, Germany.

CNTG Stock Price History

CNTG Stock News Headlines

Centogene NV: CENTOGENE Explores Strategic Alternatives
Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT?
A little-known metal called vanadium is vital to American national security and energy independence. But right now, China and Russia dominate our supply. The U.S. Govt. is so serious about vanadium, it funded and recently completed an "Earth MRI" survey to seek out new sources of this energy metal - in Wyoming.
Centogene Explores Strategic Alternatives, Incl. Sale
Centogene Announces Receipt Of Nasdaq Notice Of Delisting
CENTOGENE Explores Strategic Alternatives
Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT?
A little-known metal called vanadium is vital to American national security and energy independence. But right now, China and Russia dominate our supply. The U.S. Govt. is so serious about vanadium, it funded and recently completed an "Earth MRI" survey to seek out new sources of this energy metal - in Wyoming.
CENTOGENE Announces Preliminary Full Year 2023 Revenue
Centogene NV Ordinary Shares CNTG
EVER, BIVI and CNTG among mid-day movers
H.C. Wainwright Keeps Their Buy Rating on Centogene NV (CNTG)
CENTOGENE Reports First Half 2023 Financial Results
See More Headlines
Receive CNTG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Centogene and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/24/2021
Today
2/28/2024
Next Earnings (Estimated)
5/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical laboratories
Sub-Industry
N/A
Current Symbol
NASDAQ:CNTG
Fax
N/A
Employees
444
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$1.50
High Stock Price Target
$1.50
Low Stock Price Target
$1.50
Potential Upside/Downside
+94.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$50.71 million
Book Value
$0.29 per share

Miscellaneous

Free Float
26,559,000
Market Cap
$20.85 million
Optionable
Not Optionable
Beta
-0.73
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Ms. Kim Stratton (Age 62)
    CEO & Member of Management Board
    Comp: $930.31k
  • Mr. Jose Miguel Coego Rios
    CFO, Legal & IT and Member of Management Board
  • Dr. Peter Bauer M.D. (Age 54)
    Chief Medical & Genomic Officer and Member of Management Board
    Comp: $185.85k
  • Dr. Andrin Oswald M.D. (Age 52)
    Ph.D., Advisor
    Comp: $941.12k
  • Mr. Ian Rentsch
    Chief Commercial Officer & GM of Pharma














CNTG Stock Analysis - Frequently Asked Questions

Should I buy or sell Centogene stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Centogene in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CNTG shares.
View CNTG analyst ratings
or view top-rated stocks.

What is Centogene's stock price target for 2024?

1 brokers have issued 12 month price objectives for Centogene's stock. Their CNTG share price targets range from $1.50 to $1.50. On average, they predict the company's share price to reach $1.50 in the next twelve months. This suggests a possible upside of 89.9% from the stock's current price.
View analysts price targets for CNTG
or view top-rated stocks among Wall Street analysts.

How have CNTG shares performed in 2024?

Centogene's stock was trading at $1.20 at the beginning of 2024. Since then, CNTG stock has decreased by 34.2% and is now trading at $0.79.
View the best growth stocks for 2024 here
.

When is Centogene's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024.
View our CNTG earnings forecast
.

How were Centogene's earnings last quarter?

Centogene (NASDAQ:CNTG) posted its earnings results on Wednesday, November, 24th. The company reported ($1.08) earnings per share for the quarter, missing analysts' consensus estimates of ($0.59) by $0.49. The company earned $35.60 million during the quarter, compared to the consensus estimate of $31.91 million. During the same period last year, the business posted ($0.32) EPS.

What guidance has Centogene issued on next quarter's earnings?

Centogene updated its FY 2023 earnings guidance on Thursday, January, 18th. The company provided EPS guidance of for the period. The company issued revenue guidance of $52.2 million-$52.7 million, compared to the consensus revenue estimate of $57.6 million.

What other stocks do shareholders of Centogene own?
When did Centogene IPO?

(CNTG) raised $60 million in an IPO on Thursday, November 7th 2019. The company issued 4,000,000 shares at $14.00-$16.00 per share. SVB Leerink and Evercore ISI acted as the underwriters for the IPO and Baird and BTIG were co-managers.

How do I buy shares of Centogene?

Shares of CNTG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CNTG) was last updated on 2/28/2024 by MarketBeat.com Staff